Beyond the survey, to the ideal therapy for Asian.

IF 3.4 Q2 GASTROENTEROLOGY & HEPATOLOGY

Intestinal Research Pub Date : 2023-07-01 DOI:10.5217/ir.2023.00075

Ki Jae Jo, Jong Pil Im

{"title":"Beyond the survey, to the ideal therapy for Asian.","authors":"Ki Jae Jo, Jong Pil Im","doi":"10.5217/ir.2023.00075","DOIUrl":null,"url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 280 fections can be fatal for patients. Therefore, clinicians treating IBD must always be alert for infections. The main strategy to prevent infections is vaccination. In fact, clinical practice guidelines published by the European Crohn’s and Colitis Or ganisation and the American College of Gastroenterology stron gly recommend vaccination in patients with IBD. In addition, the global severe acute respiratory syndrome coronavirus 2 (SARSCoV2) pandemic highlighted the importance of vacci nation in immunocompromised patients and in patients with underlying chronic diseases, such as IBD; Lee et al. strongly recommended SARSCoV2 vaccination for the patients with IBD who are treated with immunosuppressants and biologic agents, since the benefits outweigh the risks. In patients with IBD, vaccines against viruses, such as hepa titis B virus, hepatitis A virus, influenza, and human papilloma virus, as well as vaccines against bacteria, such as pneumococ cus, are recommended. However, the timing of vaccinations is yet to be established. Mishra et al. reported that although hepatitis B virus vaccination in patients with ulcerative colitis showed a lower serologic response than in general population, an appropriate vaccine effect could be expected if they are not exposed to corticosteroid, immunosuppressant, or biologic agents. Therefore, several guidelines have suggested the tim ing of vaccination as either at diagnosis or just prior to starting the immunosuppressive therapy. Despite the need and recommendations for vaccination, it may not be implemented in practice for a variety of reasons. A survey of gastroenterologists’ practices regarding vaccination in patients with IBD in the United States reported that while pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00075 Intest Res 2023;21(3):280-282","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/d8/ir-2023-00075.PMC10397544.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intestinal Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5217/ir.2023.00075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 280 fections can be fatal for patients. Therefore, clinicians treating IBD must always be alert for infections. The main strategy to prevent infections is vaccination. In fact, clinical practice guidelines published by the European Crohn’s and Colitis Or ganisation and the American College of Gastroenterology stron gly recommend vaccination in patients with IBD. In addition, the global severe acute respiratory syndrome coronavirus 2 (SARSCoV2) pandemic highlighted the importance of vacci nation in immunocompromised patients and in patients with underlying chronic diseases, such as IBD; Lee et al. strongly recommended SARSCoV2 vaccination for the patients with IBD who are treated with immunosuppressants and biologic agents, since the benefits outweigh the risks. In patients with IBD, vaccines against viruses, such as hepa titis B virus, hepatitis A virus, influenza, and human papilloma virus, as well as vaccines against bacteria, such as pneumococ cus, are recommended. However, the timing of vaccinations is yet to be established. Mishra et al. reported that although hepatitis B virus vaccination in patients with ulcerative colitis showed a lower serologic response than in general population, an appropriate vaccine effect could be expected if they are not exposed to corticosteroid, immunosuppressant, or biologic agents. Therefore, several guidelines have suggested the tim ing of vaccination as either at diagnosis or just prior to starting the immunosuppressive therapy. Despite the need and recommendations for vaccination, it may not be implemented in practice for a variety of reasons. A survey of gastroenterologists’ practices regarding vaccination in patients with IBD in the United States reported that while pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00075 Intest Res 2023;21(3):280-282

查看原文本刊更多论文

超越调查，对亚洲人的理想疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Intestinal Research GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.40

自引率

10.20%

发文量

审稿时长

38 weeks

期刊介绍： Intestinal Research (Intest Res) is the joint official publication of the Asian Organization for Crohn''s and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn''s Foundation (India) (CCF, india). The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance. As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines. The Journal also seeks to propagate and exchange useful innovations, both in ideas and in practice, within the research community. As a mode of scholarly communication, it encourages scientific investigation through the rigorous peer-review system and constitutes a qualified and continual platform for sharing studies of researchers and practitioners. Specifically, the Journal presents up-to-date coverage of medical researches on the physiology, epidemiology, pathophysiology, clinical presentations, and therapeutic interventions of the intestinal diseases. General topics of interest include inflammatory bowel disease, colon and small intestine cancer or polyp, endoscopy, irritable bowel syndrome and other motility disorders, infectious enterocolitis, intestinal tuberculosis, and so forth. The Journal publishes diverse types of academic materials such as editorials, clinical and basic reviews, original articles, case reports, letters to the editor, brief communications, perspective, statement or commentary, and images that are useful to clinicians and researchers.